ATAI Life Sciences Inc.
NASADAQ: ATAI
Company Overview
atai is dedicated to acquiring, incubating and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders.
The company's business model combines funding, technology, scientific and regulatory expertise with a focus on psychedelic therapy and other drugs with differentiated safety profiles and therapeutic potential. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies, seeking to effectively treat and ultimately heal mental health disorders.
atai is headquartered in Berlin, with offices in New York.
Financial Highlights
$19,880,000
Revenue (ttm)
$0
Gross Profit (ttm)
-$11.28
Diluted EPS (ttm)
Management Team
Mr. Florian Brand
Co-Founder, MD & CEO
Dr. Srinivas G. Rao
Co-Founder & Chief Scientific Officer
Mr. Gregory L. Weaver CPA, M.B.A.
MD & CFO
Mr. Christian Angermayer
Founder & Chairman of the Supervisory Board
Mr. Lars Christian Wilde
Co-Founder
Ms. Maddy Crawford
Mang. of Accounting
Mr. Josh Elliott
Mang. of Marketing
Dr. Rolando Gutierrez-Esteinou M.D.
Chief Medical Officer
Ms. Anna Richardson
Chief of Staff & Lead of Stakeholder Engagement
Ms. Anne Johnson
Lead of Global Controller
Key Highlights
Market Capitalization
$0
Shares Outstanding
0
Shares Short (% of Float)
789,253 (0%)
Insider Ownership
10%